Triple-negative breast cancer (TNBC) accounts for 15–20% of all diagnosed BCs and is a tumor type characterized by lack of expression of three markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and neoplasm.